Dr. Russell Hall is the J. Lamar Callaway Professor in the Department of Dermatology at Duke University School of Medicine.  Dr. Hall graduated from Westminster College in Fulton, Missouri and the University of Missouri – Columbia School of Medicine.  

Dr. Hall was trained in internal medicine and dermatology at St. Louis University,   the University of Missouri- Columbia and Johns Hopkins School of Medicine. He completed a research fellowship in Dermatology Branch of the National Cancer Institute, National Institutes of Health. After 5 years at the NIH joined Duke’s faculty as an assistant professor of medicine in 1984. In 1998 Dr. Hall was named Chief of the Division of Dermatology and served in that position for more than a decade. Dr. Hall was named J. Lamar Callaway Professor of Dermatology in 2002 and played an integral role in the transition of dermatology from a division to a department serving as Chair of the Department from 2009 to 2021. 

Dr. Hall has published research in more than 145 articles in peer-reviewed publications and has contributed to more than 37 book chapters. He previously served as the deputy editor for the Journal of Investigative Dermatology. Dr. Hall is currently the Editor of the Journal of Investigative Dermatology Innovations. Dr. Hall is a member of the American Society for Clinical Investigation and the Society for Investigative Dermatology. He has also served as the Secretary-Treasurer and President of the Society for Investigative Dermatology and is currently President of the International Societies for Investigative Dermatology.  

His areas of expertise include immune mediated skin diseases. His lab has focused on examining how gastrointestinal inflammation can lead to the development of inflammatory skin disease, including dermatitis herpetiformis. Current studies are focused on the role of B cells, autoantibodies and   B cell directed therapy in the treatment and in understanding the pathogenesis of autoimmune blistering skin diseases. His clinical research has focused on the development and implementation of new therapeutic interventions for the treatment of autoimmune blistering diseases such as pemphigus and bullous pemphigoid.